Answers are grounded in this paper and cite their sources.
Systematic review and meta-analysis suggest therapeutic drug monitoring improves clinical response in systemic lupus erythematosus patients, indicating better treatment outcomes.
Among 459 reviewed abstracts, 24 met inclusion. Summarized evidence supported that clinical response was observed at MPA AUC₀₋₁₂ ≥30-35 mg h/L or Ctrough ≥1.5 mg/L. At these thresholds, therapeutic MPA levels were associated with 12-fold higher odds (95% CI 5.44-27.35, P < 0.0001, I² = 41%) of overall clinical SLE response, and 15-fold higher odds (95% CI 4.74-46.89); p < 0.0001; I²=61%) of response in patients with extra-renal manifestations. Additionally, MPA levels were 32 units higher (95% CIs 17.35-45.67) in overall SLE responders, and 39 units (95% CI 15.05-62.53) higher in patients with extra-renal manifestations. While pooled analysis did not show a significant increase in adverse events, individual studies suggested safety concerns at MPA AUC₀₋₁₂ > 60 mg h/L or Ctrough ≥2.5-3 mg/L CONCLUSIONS: This study highlights the clinical utility of TDM to guide MPA dosing to balance efficacy vs. safety in all patients with SLE, including those with extra-renal manifestations.
No takes yet. Share an insight, caveat, or question.
Qamhieh et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: